Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times

Area of Science:

• Cardiology
• Electrophysiology
• Internal Medicine

Background:

• Atrial fibrillation (AF) and heart failure (HF) are increasing global cardiovascular epidemics.
• AF negatively impacts HF prognosis, particularly with left ventricular dysfunction, increasing mortality.
• Combined AF and HF elevate thromboembolism risk due to complex pathophysiological mechanisms.

Purpose of the Study:

• To review the current understanding and management strategies for patients with coexisting atrial fibrillation and heart failure.
• To highlight the prognostic implications of AF in HF and the challenges in treatment.
• To discuss advancements in AF treatment and the importance of integrated care.

Main Methods:

• Literature review of epidemiological trends, clinical outcomes, and therapeutic interventions for AF and HF.
• Analysis of the pathophysiological links between AF and HF, including thromboembolic risk.
• Evaluation of current treatment modalities: oral anticoagulation, rate/rhythm control, catheter ablation, and device therapy.

Main Results:

• Catheter ablation for AF demonstrates superiority over medical therapy, especially for paroxysmal AF, though outcomes are less optimal for persistent AF.
• Pharmacological treatments for rate and rhythm control have limitations in efficacy and tolerability.
• Risk factor modification (obesity, sleep apnea, hypertension, diabetes) is critical, alongside interdisciplinary collaboration.

Conclusions:

• Managing patients with both AF and HF requires a comprehensive approach, integrating advanced therapies with aggressive risk factor management.
• Innovations in ablation technology and a deeper mechanistic understanding of AF are needed to improve outcomes in persistent AF.
• Effective long-term management hinges on close collaboration between heart failure specialists and electrophysiologists.